Skip to main content

Main menu

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • JRheum Supplements
  • Services

User menu

  • My Cart
  • Log In

Search

  • Advanced search
The Journal of Rheumatology
  • JRheum Supplements
  • Services
  • My Cart
  • Log In
The Journal of Rheumatology

Advanced Search

  • Home
  • Content
    • First Release
    • Current
    • Archives
    • Collections
    • Audiovisual Rheum
    • COVID-19 and Rheumatology
  • Resources
    • Guide for Authors
    • Submit Manuscript
    • Payment
    • Reviewers
    • Advertisers
    • Classified Ads
    • Reprints and Translations
    • Permissions
    • Meetings
    • FAQ
    • Policies
  • Subscribers
    • Subscription Information
    • Purchase Subscription
    • Your Account
    • Terms and Conditions
  • About Us
    • About Us
    • Editorial Board
    • Letter from the Editor
    • Duncan A. Gordon Award
    • Privacy/GDPR Policy
    • Accessibility
  • Contact Us
  • Follow jrheum on Twitter
  • Visit jrheum on Facebook
  • Follow jrheum on LinkedIn
  • Follow jrheum on YouTube
  • Follow jrheum on Instagram
  • Follow jrheum on RSS
Research ArticleArticle

Role of Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis with Coronary Calcification

KAI-HANG YIU, SILUN WANG, MO-YIN MOK, GAIK CHENG OOI, PEK-LAN KHONG, CHU-PAK LAU, WING-HON LAI, LAI-YUNG WONG, KWOK-FAI LAM, CHAK-SING LAU and HUNG-FAT TSE
The Journal of Rheumatology March 2010, 37 (3) 529-535; DOI: https://doi.org/10.3899/jrheum.090782
KAI-HANG YIU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SILUN WANG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MO-YIN MOK
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GAIK CHENG OOI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PEK-LAN KHONG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHU-PAK LAU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
WING-HON LAI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
LAI-YUNG WONG
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
KWOK-FAI LAM
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
CHAK-SING LAU
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
HUNG-FAT TSE
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: hftse@hkucc.hku.hk
  • Article
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters
PreviousNext
Loading

Abstract

Objective. Patients with rheumatoid arthritis (RA) are prone to premature atherosclerosis. We hypothesize that depletion of circulating endothelial progenitor cells (EPC) related to RA can contribute to the development of atherosclerosis.

Methods. We studied coronary calcifications by multidetector computed tomography and their relationship with different subtypes of circulating EPC in 70 patients with RA and 35 age- and sex-matched controls (mean age 54.1 ± 10.2 yrs, 87% were women). The presence of coronary atherosclerosis was defined as an Agatston score ≥ 10. Four subpopulations of EPC were determined by flow cytometry on the basis of surface expression of CD34, CD133, and KDR antigen: CD34+, CD34/KDR+, CD133+, and CD133/KDR+ EPC, respectively.

Results. Among those with RA, 15 patients (21%) had coronary atherosclerosis. The mean Agatston score was higher (61.8 ± 201.7 vs 0.14 ± 0.69; p = 0.01) and coronary atherosclerosis was more prevalent (21.4% vs 0%; p < 0.01) in patients with RA compared to controls. RA patients with coronary atherosclerosis were older (66.2 ± 6.9 vs 51.5 ± 16.2 yrs; p < 0.01), had higher prevalence of hypertension (46.7% vs 14.5%; p = 0.01), and had lower CD133/KDR+ (0.45% ± 0.28% vs 0.89% ± 0.81%; p < 0.01) and CD133+ EPC levels (0.74% ± 0.39% vs 1.22% ± 0.83%; p < 0.01), but similar CD34/KDR+ and CD34+ EPC levels (all p > 0.05) compared to those without. Multiple logistic regression revealed that older age (OR 1.25, 95% CI 1.10–1.41, p < 0.01) and lower CD133/KDR+ EPC (OR 0.07, 95% CI 0.00–0.97, p < 0.01) were independent predictors for coronary atherosclerosis in patients with RA.

Conclusion. Our results demonstrated that RA patients with coronary atherosclerosis have significantly lower levels of CD133/KDR+ and CD133+ EPC than those without. In addition to older age, lower levels of circulating CD133/KDR+ EPC also predicted occurrence of coronary atherosclerosis in RA patients.

  • RHEUMATOID ARTHRITIS
  • ENDOTHELIAL PROGENITOR CELLS
  • ARTERIAL CALCIFICATION

Patients with rheumatoid arthritis (RA) have increased cardiovascular mortality compared with the general population1–5. Although the mechanisms remain unclear, it is well established that their excess cardiovascular morbidity and mortality is attributed to an increased risk of acute myocardial infarction and coronary heart disease mortality6–8. In addition, conventional risk factors cannot fully explain the accelerated atherosclerosis observed in patients with RA9. As a result, it has been postulated that the chronic inflammatory state associated with RA may contribute to the accelerated atherosclerosis. Indeed, previous studies have demonstrated that patients with RA have premature atherosclerosis with an increased prevalence and severity of coronary artery calcification10,11 and greater intima-media thickness (IMT)12,13 compared with age-matched controls. Our recent studies also showed that patients with RA have premature and diffuse arterial calcification over multiple vascular beds14.

Experimental studies suggest that bone marrow-derived endothelial progenitor cells (EPC) play an important role in the maintenance of endothelial integrity and hemostasis15. The number of circulating EPC has been shown to be inversely correlated with cardiovascular risk factors and vascular function16,17 and to predict cardiovascular events18. Prior studies showed that RA is associated with depletion of circulating EPC, which correlates with impaired brachial endothelial function19 and increased carotid IMT20,21. However, the relationship between the circulating EPC and subclinical coronary atherosclerosis as determined by coronary calcification remains unclear. Further, the relationship of different subtypes of EPC with coronary atherosclerosis is also unknown. We hypothesized that depletion of different subtypes of circulating EPC is associated with increased coronary atherosclerosis as detected by multidetector computer tomography (MDCT) in patients with RA.

MATERIALS AND METHODS

Study population

From January 2006 to January 2007, 77 consecutive Chinese patients age > 18 years who met American College of Rheumatology (formerly, the American Rheumatism Association) classification criteria for RA were recruited22. Patients with a documented history of cardiovascular disease including coronary artery disease (n = 3), myocardial infarction (n = 3), or stroke (n = 1) were excluded. As a result, our study involved 70 RA patients without established cardiovascular diseases. During the study period, 35 age- and sex-matched (1:2 matching) controls were recruited from the health-check program organized by the hospital. For comparison, Chinese controls who did not meet classification criteria for RA or other inflammatory disease were also recruited from a community health screening program. The study was approved by the institutional ethical review board and all subjects gave their written informed consent.

Study protocols

Baseline demographic and clinical characteristics, blood sampling, and MDCT were obtained prospectively on the same day in all study subjects. Cardiovascular risk factors including diabetes mellitus, hypercholesterolemia, and hypertension were assessed. Body height and weight and blood pressure of all subjects were measured as described23. Hypertension was defined as either resting systolic or diastolic blood pressure ≥ 140/90 mm Hg on 2 occasions or prescription of antihypertensive medication. Diabetes mellitus was defined as a serum fasting glucose ≥ 7.1 mmol/l or prescription of antihyperglycemic medication. Hypercholesterolemia was defined as a fasting total serum cholesterol level of ≥ 4.9 mmol/l or prescription of statin. For patients with RA, data on rheumatoid factor, inflammatory markers, current use of disease-modifying antirheumatic drugs (DMARD), prednisolone, and nonsteriodal antiinflammatory drugs were retrieved from medical records. In our study, none of the RA patients were treated with biological agents.

Fasting blood samples were obtained from all subjects to determine serum creatinine, glucose, and lipid levels. C-reactive protein level (CRP) was measured using a Hitachi 747 analyzer (Boehringer Mannheim, Mannheim, Germany) and a particle-enhanced immunoturbidimetric assay (Roche Diagnostics, Mannheim, Germany) as described24.

MDCT imaging

All subjects underwent coronary CT scan using a 64-slice MDCT as described (Lightspeed, VCT, GE Healthcare, Princeton, NJ, USA)14. In brief, all scans were performed with subjects in the supine position and included regions from the aortic arch to the fundus of the heart. A prospective electrocardiogram-gated cardiac scan was obtained with the following scan parameters: rotation time 0.35 s; slice thickness 2.5 mm; 120 kV; 250 mA; trigger delay 70% R-R interval. Patients were instructed to hold their breath for 30 s during scanning.

MDCT images were reviewed at the post-processing image workstation (Advantage Windows 4.02, GE Healthcare). Complete data were available from all the scans, without misregistration of slices due to artifacts of motion, respiration, or asynchronous electrocardiographic triggering. To ensure the continuity and consistency of the interpretation of coronary calcium scores (CCS), 2 expert investigators (SW, GCO), who were unaware of the subjects’ clinical status, analyzed all the scans. The interobserver and intraobserver variability correlation coefficients of calcium score measurements were 0.92 and 0.91, respectively.

Analysis of MDCT calcium score

Measurement of CCS was performed using commercial “SmartScore” software (GE Healthcare) with the threshold option set for pixels > 130 Hounsfield units and expressed in Agatston units. CCS was calculated as the sum of CCS in the left main coronary artery, left anterior descending artery, left circumflex coronary artery, right coronary artery, and posterior descending artery14. A CCS score of ≥ 10 Agatston score was considered as the presence of significant coronary atherosclerosis23.

Flow cytometry

The circulating EPC were determined by the expression of surface markers CD34+, CD133+, and KDR+ on mononuclear cells, and their numbers were measured by fluorescence-activated cell analysis of peripheral blood sample as described24. In brief, 100 μl of peripheral blood was incubated with a phycoerythrin-conjugated monoclonal antibody against human KDR (Sigma, St. Louis, MO, USA), followed by a fluorescein isothiocyanate (FITC)-conjugated CD34 and CD133 antibodies (Beckman Coulter, Fullerton, CA, USA). FITC-labeled anti-human CD45 antibody was used for differential gating during flow analysis. FITC-labeled IgG1a (Beckman Coulter) and phycoerythrin-labeled IgG2b (Becton Dickinson, Franklin Lakes, NJ, USA) served as the isotypic control for color compensation. Analysis was performed with an automated fluorescence-activated cell counter (Elite, Beckman Coulter) in which 1,000,000 events were counted. The percentages of all the measured components defined as the absolute cell counts divided by the lymphocyte counts were calculated. The intraobserver variability testing found an intraclass correlation coefficient of 0.9 (p < 0.001).

Statistical analysis

Continuous variables were presented as mean ± standard deviation or median (range, interquartile range) for the Agatston score as the distribution is highly skewed. Categorical data were presented as frequencies and percentages. Continuous variables were tested for normal distribution with the Kolmogorov-Smirnov test. Statistical comparisons were performed by using Student’s t test and Wilcoxon rank-sum test for continuous variables with and without valid normality assumption, respectively, and Fishers’ exact test for discrete variables. Simple logistic regression analysis was used to evaluate the odds ratios (OR) and confidence intervals (CI) for Agatston score > 10 in patients with RA. Multiple logistic regression analyses were performed. The final model was obtained using a backward elimination method by deleting the most insignificant variable. All statistical analyses were performed using SPSS for Windows (Version 15.0, SPSS, Chicago, IL, USA). All p values are 2-sided, while p < 0.05 was considered statistically significant.

RESULTS

Clinical characteristics

Demographic characteristics of the study population are shown in Table 1. The mean age of the overall study population was 54.1 ± 10.2 years, and a majority of patients were female (87%). In patients with RA, the mean duration of RA disease was 12.7 ± 10.7 years, and 49 of them (70%) had positive rheumatoid factor. More than two-thirds of patients were taking DMARD, and 17% prednisolone. There were no significant differences in the clinical and biochemical characteristics between control subjects and patients with RA, except that patients with RA had a higher prevalence of hypertension (Table 1). Further, there were no significant differences in the mean percentages of circulating CD34+, CD34/KDR+, CD133+, and CD133/KDR+ EPC between control subjects and patients with RA (Table 1).

View this table:
  • View inline
  • View popup
Table 1.

Clinical characteristics in patients with and without coronary atherosclerosis (CA).

Compared with controls, patients with RA had higher mean Agatston score (61.8 ± 201.7 vs 0.14 ± 0.69; p = 0.01). Among those with RA, 15 patients (21%) had coronary atherosclerosis (defined by CCS scores ≥ 10) compared to no controls (0%; p < 0.01). As shown in Table 1, patients with RA who had coronary atherosclerosis were older (66.2 ± 6.9 vs 51.5 ± 16.2 years; p < 0.01) and had higher prevalence of hypertension (46.7% vs 14.5%; p = 0.01), systolic blood pressure (143.3 ± 14.2 vs 122.5 ± 18.1 mm Hg; p < 0.01), and diastolic blood pressure (80.8 ± 10.9 vs 73.4 ± 10.7 mm Hg; p = 0.03). However, there were no significant differences in the prevalence of other cardiovascular risk factors, medications, CRP, and presence of rheumatoid factor between RA patients with and without coronary atherosclerosis.

EPC and coronary atherosclerosis

As shown in Table 1, there were no significant differences in the percentages of circulating CD34/KDR+ EPC and CD34+ EPC between RA patients with or without coronary atherosclerosis and control subjects. However, the percentages of circulating CD133+ EPC and CD133/KDR+ EPC were significantly lower in RA patients with coronary atherosclerosis compared with those without coronary atherosclerosis and control subjects (Table 1; all p < 0.01). Nevertheless, there were no significant correlations between CCS and different subgroups of circulating EPC in patients with RA (CD34/KDR+ EPC: r = 0.09, p = 0.45; CD34+ EPC: r = 0.96, p = 0.43; CD133/KDR+ EPC: r = −0.14, p = 0.25; CD133+ EPC: r = −0.12, p = 0.33).

EPC and clinical characteristics

As shown in Table 2, there were no significant correlations between different subgroups of circulating EPC with age, duration of RA, systolic and diastolic blood pressure, serum total cholesterol, triglyceride, and high or low density lipoprotein. However, there was a significant but only modest inverse relationship between CRP and CD133/KDR+ EPC (r = −0.27, p = 0.02).

View this table:
  • View inline
  • View popup
Table 2.

Correlations of endothelial progenitor cell (EPC) subgroups and clinical variables.

Further, there were no significant differences in the mean percentages of circulating CD34+ (6.30% ± 4.46% vs 6.25% ± 5.40%; p = 0.75), CD34/KDR+ (2.81% ± 3.29% vs 2.56% ± 2.94%; p = 0.97), CD133+ (1.19% ± 0.77% vs 0.98% ± 0.80%; p = 0.30), and CD133/KDR+ EPC (0.81% ± 0.74% vs 0.76% ± 0.78%; p = 0.80) between RA patients with and those without DMARD treatment.

Predictors of coronary atherosclerosis in RA

Univariate analysis demonstrated that RA patients with coronary atherosclerosis were associated with older age, a higher prevalence of hypertension, and a lower circulating percentage of CD133+ EPC (Table 3; p < 0.05). However, multiple logistic regression analysis revealed that older age (OR 1.25, 95% CI 1.10–1.41; p < 0.01) and lower level of CD133/KDR+ EPC (OR 0.07, 95% CI 0.00–0.97; p < 0.01) were independent predictors for coronary atherosclerosis in patients with RA (Table 3).

View this table:
  • View inline
  • View popup
Table 3.

Predictors for coronary atherosclerosis by univariate and multivariate multiple logistic regression.

DISCUSSION

In our study, different subgroups of circulating EPC were measured in patients with RA, and their relationships with the occurrence of subclinical coronary atherosclerosis were examined. Patients with RA had significantly higher mean CCS scores as well as prevalence of coronary atherosclerosis versus age- and sex-matched controls. In RA patients with coronary atherosclerosis, percentages of circulating CD133+ and CD133/KDR+ EPC were significantly lower than in those without coronary atherosclerosis. Further, the circulating level of CD133/KDR+ EPC was inversely correlated with CRP level. As well, multiple logistic regression analysis revealed that older age and lower level of CD133/KDR+ EPC were independent predictors of coronary atherosclerosis in patients with RA.

In concordance with prior studies25,26, our results confirm that in patients with RA the presence of premature atherosclerosis as detected by coronary calcification was not associated with the majority of conventional cardiovascular risk factors, except for age. Previous clinical studies showed that duration and severity of RA might account for development of premature atherosclerosis as measured by carotid IMT25–27. These findings25–27 suggest the potentially pivotal role of chronic inflammation in the pathogenesis of premature atherosclerosis. In our study, there was no significant correlation between CRP levels and severity of coronary atherosclerosis. In line with our results, Chung, et al also did not observe any relationship between CRP level and CCS in patients with RA. As RA is a chronic inflammatory condition, a single measurement of CRP should not be able to reflect the inflammatory burden in patients with RA.

Several studies have shown that depletion of circulating EPC is observed in patients with RA compared with controls19–21. However, there were no significant differences in different subgroups of EPC between RA patients and controls in our study. This may be related to the overall low disease activity in our cohort of RA patients as reflected by a similar CRP level compared to controls. Indeed, Grisar, et al demonstrated that RA patients with low disease activity score had comparable EPC levels versus control subjects19. Nevertheless, our results showed that RA patients with coronary atherosclerosis had significantly lower levels of CD133/KDR+ EPC than controls and those RA patients without coronary atherosclerosis. Further, RA patients without coronary atherosclerosis had EPC levels similar to those of controls. These findings suggest a potential link between depletion of CD133/KDR+ EPC and coronary atherosclerosis in patients with RA.

A comprehensive role of EPC in patients with RA after direct atherosclerotic assessment has not been fully validated. Recent studies demonstrated that measurement of coronary calcification is a reliable way to detect early atherosclerosis in asymptomatic patients and is a powerful surrogate marker for future cardiovascular events27,28. Studies10,11 have shown a higher incidence of coronary calcification in patients with RA compared with control subjects. In addition, our recent study14 highlighted the occurrence of premature and extensive calcification over multiple vascular beds in patients with RA. In our study, we hypothesized that chronic inflammation is associated with the depletion of circulating EPC, which subsequently contributes to the development of coronary atherosclerosis. Accordingly, measurement of circulating EPC levels may be more accurate in predicting development of coronary atherosclerosis. Further, the possible relationships of coronary atherosclerosis with different subgroups of EPC were also studied.

Since the initial report by Asahara, et al29, EPC have been defined by surface expression of CD34 and KDR. As a result, the majority of subsequent studies have focused on the relationship between CD34/KDR+ EPC and development of atherosclerosis30,31. After mobilization from the bone marrow into the peripheral circulation, more mature EPC are negative for CD133 but are positive for CD34 and KDR32,33. Therefore, CD133+ or CD133/KDR+ EPC and CD34+ or CD34/KDR+ EPC represent subgroups of immature and mature EPC in the circulation, respectively.

Further, the co-expression of KDR with CD133 or CD34 is also a more specific marker for EPC than the presence of either CD133 or CD34 alone. In addition, the expression of CD133/CD34/KDR may represent an intermediate stage of EPC maturation. However, the presence of CD133/CD34/KDR EPC was not determined in the present study. Our results showed that RA patients with coronary atherosclerosis had significantly lower levels of CD133+ and CD133/KDR+ immature EPC, but not CD34+ and CD34/KDR+ mature EPC, compared to those without coronary atherosclerosis. Further, the circulating level of CD133/KDR+ EPC also only inversely correlated with the CRP level, but not with the other cardiovascular risk factors, suggesting that active inflammation might contribute to a lower level of EPC in patients with RA. Although the exact mechanism remains unclear, alteration of chemokine expression in RA patients related to chronic inflammation might have a greater influence on immature EPC than mature EPC34.

Multiple logistic regression analysis demonstrated that in addition to older age, low level of CD133/KDR+ EPC was an independent predictor for coronary atherosclerosis in patients with RA. Prior studies have shown the potential association between depletion of EPC and atherosclerosis as measured by carotid IMT19. Our findings not only confirmed this result but further demonstrated that depletion of the population of immature EPC was associated with the development of coronary atherosclerosis in patients with RA.

Study limitations

First, this was a cross-sectional observational study and the causal relationship between EPC and arterial atherosclerosis in patients with RA could not be assessed. Second, the functional and proliferative activities of EPC were not determined; these require further studies to identify their role in development of premature atherosclerosis. Third, clinical disease activity, using instruments such as the Disease Activity Score-28, was not measured in our cohort. Nevertheless, measurement of CRP in this study is probably more representative of inflammatory activities as these disease scores include certain assessments that could be subjective and not necessarily inflammatory.

Our study demonstrated that RA patients with coronary atherosclerosis as determined by CCS was associated with depletion of primordial CD133+ and CD133+KDR+ EPC but not mature CD34+ and CD34+KDR+ EPC. Further, circulating levels of CD133/KDR+ EPC independently predicted occurrence of coronary atherosclerosis. These findings suggest that depletion of EPC observed in RA patients could at least partly explain the occurrence of premature coronary atherosclerosis in patients with RA.

Footnotes

  • Supported by the Sun Chieh Yeh Heart Foundation.

    • Accepted for publication October 14, 2009.

REFERENCES

  1. 1.↵
    1. del Rincon I,
    2. Williams K,
    3. Stern MP,
    4. Freeman GL,
    5. Escalante A
    . High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737–45.
    OpenUrlCrossRefPubMed
  2. 2.↵
    1. Wolfe F,
    2. Freundlich B,
    3. Straus WL
    . Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36–40.
    OpenUrlAbstract/FREE Full Text
  3. 3.↵
    1. Solomon DH,
    2. Karlson EW,
    3. Rimm EB,
    4. Cannuscio CC,
    5. Mandl LA,
    6. Manson JE,
    7. et al.
    Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303–7.
    OpenUrlAbstract/FREE Full Text
  4. 4.↵
    1. Maradit-Kremers H,
    2. Nicola PJ,
    3. Crowson CS,
    4. Ballman KV,
    5. Gabriel SE
    . Cardiovascular death in rheumatoid arthritis: a population-based study. Arthritis Rheum 2005;52:722–32.
    OpenUrlCrossRefPubMed
  5. 5.↵
    1. Goodson N,
    2. Marks J,
    3. Lunt M,
    4. Symmons D
    . Cardiovascular admissions and mortality in an inception cohort of patients with rheumatoid arthritis with onset in the 1980s and 1990s. Ann Rheum Dis 2005;64:1595–601.
    OpenUrlAbstract/FREE Full Text
  6. 6.↵
    1. Watson DJ,
    2. Rhodes T,
    3. Guess HA
    . All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196–202.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Van Doornum S,
    2. Brand C,
    3. King B,
    4. Sundararajan V
    . Increased case fatality rates following a first acute cardiovascular event in patients with rheumatoid arthritis. Arthritis Rheum 2006;54:2061–8.
    OpenUrlCrossRefPubMed
  8. 8.↵
    1. Maradit-Kremers H,
    2. Crowson CS,
    3. Nicola PJ,
    4. Ballman KV,
    5. Roger VL,
    6. Jacobsen SJ,
    7. et al.
    Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum 2005;52:402–11.
    OpenUrlCrossRefPubMed
  9. 9.↵
    1. Manzi S,
    2. Wasko MC
    . Inflammation-mediated rheumatic diseases and atherosclerosis. Ann Rheum Dis 2000;59:321–5.
    OpenUrlFREE Full Text
  10. 10.↵
    1. Chung C,
    2. Long A,
    3. Solus J,
    4. Rho Y,
    5. Oeser A,
    6. Raggi P,
    7. et al.
    Increased coronary-artery atherosclerosis in rheumatoid arthritis: relationship to disease duration and cardiovascular risk factors. Arthritis Rheum 2005;52:3045–53.
    OpenUrlCrossRefPubMed
  11. 11.↵
    1. Kao AH,
    2. Wasko MC,
    3. Krishnaswami S,
    4. Wagner J,
    5. Edmundowicz D,
    6. Shaw P,
    7. et al.
    C-reactive protein and coronary artery calcium in asymptomatic women with systemic lupus erythematosus or rheumatoid arthritis. Am J Cardiol 2008;102:755–60.
    OpenUrlCrossRefPubMed
  12. 12.↵
    1. Roman MJ,
    2. Moeller E,
    3. Davis A,
    4. Paget SA,
    5. Crow MK,
    6. Lockshin MD,
    7. et al.
    Preclinical carotid atherosclerosis in patients with rheumatoid arthritis. Ann Intern Med 2006;144:249–56.
    OpenUrlCrossRefPubMed
  13. 13.↵
    1. Gonzalez-Juanatey C,
    2. Llorca J,
    3. Martin J,
    4. Gonzalez-Gay MA
    . Carotid intima-media thickness predicts the development of cardiovascular events in patients with rheumatoid arthritis. Semin Arthritis Rheum 2009;38:366–71.
    OpenUrlCrossRefPubMed
  14. 14.↵
    1. Wang S,
    2. Yiu KH,
    3. Mok MY,
    4. Ooi GC,
    5. Khing PL,
    6. Mak KF,
    7. et al.
    Prevalence and extent of calcification over aorta, coronary and carotid arteries in patients with rheumatoid arthritis. J Intern Med 2009;266:445–52. Epub 2009 Apr 23
    OpenUrlCrossRefPubMed
  15. 15.↵
    1. Vasa M,
    2. Fichtlscherer S,
    3. Aicher A,
    4. Adler K,
    5. Urbich C,
    6. Martin H,
    7. et al.
    Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001;89:E1–7.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Szmitko PE,
    2. Fedak PW,
    3. Weisel RD,
    4. Stewart DJ,
    5. Kutryk MJ,
    6. Verma S
    . Endothelial progenitor cells: new hope for a broken heart. Circulation 2003;107:3093–100.
    OpenUrlFREE Full Text
  17. 17.↵
    1. Hill JM,
    2. Zalos G,
    3. Halcox JP,
    4. Schenke WH,
    5. Waclawiw MA,
    6. Quyyumi AA,
    7. et al.
    Circulating endothelial progenitor cells, vascular function, and cardiovascular risk. N Engl J Med 2003;348:593–600.
    OpenUrlCrossRefPubMed
  18. 18.↵
    1. Werner N,
    2. Kosiol S,
    3. Schiegl T,
    4. Ahlers P,
    5. Walenta K,
    6. Link A,
    7. et al.
    Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med 2005;353:999–1007.
    OpenUrlCrossRefPubMed
  19. 19.↵
    1. Grisar J,
    2. Aletaha D,
    3. Steiner CW,
    4. Kapral T,
    5. Steiner S,
    6. Seidinger D,
    7. et al.
    Depletion of endothelial progenitor cells in the peripheral blood of patients with rheumatoid arthritis. Circulation 2005;111:204–11.
    OpenUrlAbstract/FREE Full Text
  20. 20.↵
    1. Herbrig K,
    2. Haensel S,
    3. Oelschlaegel U,
    4. Pistrosch F,
    5. Foerster S,
    6. Passauer J
    . Endothelial dysfunction in patients with rheumatoid arthritis is associated with a reduced number and impaired function of endothelial progenitor cells. Ann Rheum Dis 2006;65:157–63.
    OpenUrlAbstract/FREE Full Text
  21. 21.↵
    1. Surdacki A,
    2. Martens-Lobenhoffer J,
    3. Wloch A,
    4. Marewicz E,
    5. Rakowski T,
    6. Wieczorek-Surdacka E,
    7. et al.
    Elevated plasma asymmetric dimethyl-L-arginine levels are linked to endothelial progenitor cell depletion and carotid atherosclerosis in rheumatoid arthritis. Arthritis Rheum 2007;56:809–19.
    OpenUrlCrossRefPubMed
  22. 22.↵
    1. Arnett FC,
    2. Edworthy SM,
    3. Bloch DA,
    4. McShane DJ,
    5. Fries JF,
    6. Cooper NS,
    7. et al.
    The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315–24.
    OpenUrlCrossRefPubMed
  23. 23.↵
    1. Shaw LJ,
    2. Raggi P,
    3. Schisterman E,
    4. Berman D,
    5. Callister TQ
    . Prognostic value of cardiac risk factors and coronary artery calcium screening for all-cause mortality. Radiology 2003;228:826–33.
    OpenUrlCrossRefPubMed
  24. 24.↵
    1. Lau KK,
    2. Chan YH,
    3. Yiu KH,
    4. Li SW,
    5. Tam S,
    6. Lau CP,
    7. et al.
    Burden of carotid atherosclerosis in patients with stroke: relationships with circulating endothelial progenitor cells and hypertension. J Hum Hypertens 2007;21:445–5.
    OpenUrlPubMed
  25. 25.↵
    1. Del Rincon I,
    2. Williams K,
    3. Stern MP,
    4. Freeman GL,
    5. O’Leary DH,
    6. Escalante A
    . Association between carotid atherosclerosis and markers of inflammation in rheumatoid arthritis patients and healthy subjects. Arthritis Rheum 2003;48:1833–40.
    OpenUrlCrossRefPubMed
  26. 26.↵
    1. Gonzalez-Gay MA,
    2. Gonzalez-Juanatey C,
    3. Piñeiro A,
    4. Garcia-Porrua C,
    5. Testa A,
    6. Llorca J
    . High-grade C-reactive protein elevation correlates with accelerated atherogenesis in patients with rheumatoid arthritis. J Rheumatol 2005;32:1219–23.
    OpenUrlAbstract/FREE Full Text
  27. 27.↵
    1. Detrano R,
    2. Guerci AD,
    3. Carr JJ,
    4. Bild DE,
    5. Burke G,
    6. Folsom AR,
    7. et al.
    Coronary calcium as a predictor of coronary events in four racial or ethnic groups. N Engl J Med 2008;358:1336–45.
    OpenUrlCrossRefPubMed
  28. 28.↵
    1. Budoff MJ,
    2. Diamond GA,
    3. Raggi P,
    4. Arad Y,
    5. Guerci AD,
    6. Callister TQ,
    7. et al.
    Continuous probabilistic prediction of angiographically significant coronary artery disease using electron beam tomography. Circulation 2002;105:1791–6.
    OpenUrlAbstract/FREE Full Text
  29. 29.↵
    1. Asahara T,
    2. Murohara T,
    3. Sullivan A,
    4. Silver M,
    5. van der Zee R,
    6. Li T,
    7. et al.
    Isolation of putative progenitor endothelial cells for angiogenesis. Science 1997;275:964–7.
    OpenUrlAbstract/FREE Full Text
  30. 30.↵
    1. Chironi G,
    2. Walch L,
    3. Pernollet MG,
    4. Gariepy J,
    5. Levenson J,
    6. Rendu F,
    7. et al.
    Decreased number of circulating CD34+KDR+ cells in asymptomatic subjects with preclinical atherosclerosis. Atherosclerosis 2007;191:115–20.
    OpenUrlCrossRefPubMed
  31. 31.↵
    1. Fadini GP,
    2. Coracina A,
    3. Baesso I,
    4. Agostini C,
    5. Tiengo A,
    6. Avogaro A,
    7. et al.
    Peripheral blood CD34+KDR+ endothelial progenitor cells are determinants of subclinical atherosclerosis in a middle-aged general population. Stroke 2006;37:2277–82.
    OpenUrlAbstract/FREE Full Text
  32. 32.↵
    1. Gehling UM,
    2. Ergun S,
    3. Schumacher U,
    4. Wagener C,
    5. Pantel K,
    6. Otte M,
    7. et al.
    In vitro differentiation of endothelial cells from AC133-positive progenitor cells. Blood 2000;95:3106–12.
    OpenUrlAbstract/FREE Full Text
  33. 33.↵
    1. Friedrich EB,
    2. Walenta K,
    3. Scharlau J,
    4. Nickenig G,
    5. Werner N
    . CD34−/CD133+/VEGFR-2+ endothelial progenitor cell subpopulation with potent vasoregenerative capacities. Circ Res 2006;98:e20–25.
    OpenUrlAbstract/FREE Full Text
  34. 34.↵
    1. Henneken M,
    2. Dörner T,
    3. Burmester GR,
    4. Berek C
    . Differential expression of chemokine receptors on peripheral blood B cells from patients with rheumatoid arthritis and systemic lupus erythematosus. Arthritis Res Ther 2005;7:R1001–13.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

The Journal of Rheumatology
Vol. 37, Issue 3
1 Mar 2010
  • Table of Contents
  • Table of Contents (PDF)
  • Index by Author
  • Editorial Board (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Rheumatology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Role of Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis with Coronary Calcification
(Your Name) has forwarded a page to you from The Journal of Rheumatology
(Your Name) thought you would like to see this page from the The Journal of Rheumatology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Role of Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis with Coronary Calcification
KAI-HANG YIU, SILUN WANG, MO-YIN MOK, GAIK CHENG OOI, PEK-LAN KHONG, CHU-PAK LAU, WING-HON LAI, LAI-YUNG WONG, KWOK-FAI LAM, CHAK-SING LAU, HUNG-FAT TSE
The Journal of Rheumatology Mar 2010, 37 (3) 529-535; DOI: 10.3899/jrheum.090782

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero

 Request Permissions

Share
Role of Circulating Endothelial Progenitor Cells in Patients with Rheumatoid Arthritis with Coronary Calcification
KAI-HANG YIU, SILUN WANG, MO-YIN MOK, GAIK CHENG OOI, PEK-LAN KHONG, CHU-PAK LAU, WING-HON LAI, LAI-YUNG WONG, KWOK-FAI LAM, CHAK-SING LAU, HUNG-FAT TSE
The Journal of Rheumatology Mar 2010, 37 (3) 529-535; DOI: 10.3899/jrheum.090782
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
    • Abstract
    • MATERIALS AND METHODS
    • RESULTS
    • DISCUSSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • References
  • PDF
  • eLetters

Related Articles

Cited By...

More in this TOC Section

  • Comparative Effectiveness of BNT162b2 and mRNA-1273 Vaccines Against COVID-19 Infection Among Patients With Systemic Autoimmune Rheumatic Diseases on Immunomodulatory Medications
  • Clinimetric Validation of the Assessment of Spondyloarthritis International Society Health Index in Patients With Radiographic Axial Spondyloarthritis in Ixekizumab Trials
  • Sex-Specific Differences in Patients With Psoriatic Arthritis: A Systematic Review
Show more Articles

Similar Articles

Content

  • First Release
  • Current
  • Archives
  • Collections
  • Audiovisual Rheum
  • COVID-19 and Rheumatology

Resources

  • Guide for Authors
  • Submit Manuscript
  • Author Payment
  • Reviewers
  • Advertisers
  • Classified Ads
  • Reprints and Translations
  • Permissions
  • Meetings
  • FAQ
  • Policies

Subscribers

  • Subscription Information
  • Purchase Subscription
  • Your Account
  • Terms and Conditions

More

  • About Us
  • Contact Us
  • My Alerts
  • My Folders
  • Privacy/GDPR Policy
  • RSS Feeds
The Journal of Rheumatology
The content of this site is intended for health care professionals.
Copyright © 2022 by The Journal of Rheumatology Publishing Co. Ltd.
Print ISSN: 0315-162X; Online ISSN: 1499-2752
Powered by HighWire